BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Burghi G, Biard L, Roux A, Valade S, Robert-Gangneux F, Hamane S, Maubon D, Debourgogne A, Le Gal S, Dalle F, Leterrier M, Toubas D, Pomares C, Bellanger AP, Bonhomme J, Berry A, Iriart X, Durand-Joly I, Magne D, Pons D, Hennequin C, Maury E, Azoulay E, Lemiale V. Characteristics and outcome according to underlying disease in non-AIDS patients with acute respiratory failure due to Pneumocystis pneumonia. Eur J Clin Microbiol Infect Dis 2021;40:1191-8. [PMID: 33411170 DOI: 10.1007/s10096-020-04118-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Hammarström H, Krifors A, Athlin S, Friman V, Golestani K, Hällgren A, Otto G, Oweling S, Pauksens K, Kinch A, Blennow O. Treatment with reduced dose trimethoprim-sulfamethoxazole is effective in mild to moderate Pneumocystis jirovecii pneumonia in patients with hematologic malignancies. Clin Infect Dis 2022:ciac386. [PMID: 35594562 DOI: 10.1093/cid/ciac386] [Reference Citation Analysis]
2 Liu Y, Zhu H, Zheng Y. Detection of Pneumocystis jirovecii Pneumonia in Infants with Non-Human Immunodeficiency Virus Admitted to Pediatric Intensive Care Using Metagenomics Next-Generation Sequencing. IDR 2022;Volume 15:1889-902. [DOI: 10.2147/idr.s358483] [Reference Citation Analysis]
3 Gingerich AD, Norris KA, Mousa JJ. Pneumocystis Pneumonia: Immunity, Vaccines, and Treatments. Pathogens 2021;10:236. [PMID: 33669726 DOI: 10.3390/pathogens10020236] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]